Introduction
============

The diabetic neuropathies comprise a family of nerve disorders that are common complications of diabetes and can result in chronic, persistent, neuropathic pain.[@b1-dmso-4-401] These neuropathies occur with a similar frequency among patients with type 1 and type 2 diabetes, 59% and 66%, respectively.[@b2-dmso-4-401] Painful diabetic peripheral neuropathy (pDPN) is a variant of distal symmetrical sensorimotor polyneuropathy, the most common form of diabetic neuropathy.[@b3-dmso-4-401] Although best estimates suggest that only 15% of patients with diabetes have pDPN,[@b1-dmso-4-401] the symptoms of chronic pain and reduced function have a profound impact on patients and result in a substantial burden relative to both the general population and to diabetic patients without pDPN.[@b1-dmso-4-401],[@b4-dmso-4-401]--[@b14-dmso-4-401]

Although updated guidelines for the treatment of neuropathic pain have recently been published,[@b15-dmso-4-401]--[@b18-dmso-4-401] treatment of pDPN remains challenging, especially given the presence of comorbidities, contraindications, and use of other medications with potential interactions.[@b19-dmso-4-401]

Understanding pDPN severity and its impact on the patient and societal burdens can help inform development and application of appropriate management strategies. In particular, given the subjective and multidimensional nature of pain, such an understanding is especially important when considered from the patients' perspective.

The identification of established cut points for characterizing mild, moderate, and severe pain associated with pDPN[@b20-dmso-4-401] has enhanced the ability to evaluate the relationship between pain and other outcomes. Several studies have evaluated these relationships, and reported that the magnitude of the effects of pDPN pain on outcomes of function, sleep, quality of life, depression, and anxiety was higher at greater levels of pain severity.[@b9-dmso-4-401]--[@b11-dmso-4-401],[@b21-dmso-4-401] However, a broader approach that considers severity of pDPN as a condition, not just pain severity, may provide a more clinically relevant patient perspective of severity and impact. Such an approach has been used in other painful conditions including osteoarthritis and chronic low back pain.[@b22-dmso-4-401]--[@b24-dmso-4-401] Additionally, only limited quantitative data exist on the impact of pDPN on productivity. One study reported that lost productive time among diabetic patients with neuropathic symptoms was higher than among diabetic patients without such symptoms, and 18% higher than non-diabetic controls.[@b6-dmso-4-401] A more recent study demonstrated that work productivity was significantly lower with increasing pain severity, and that costs related to lost productivity increased with greater levels of pain.[@b21-dmso-4-401] Therefore, the purpose of this study was to explore the relationship between patient-reported severity of pDPN and health indicators, as well as to quantitatively assess the impact of pDPN severity on productivity.

Methods
=======

Data source
-----------

The Adelphi Disease Specific Program (DSP) represents an aggregated database from a cross sectional study of consulting patients, which includes patient-level and physician-reported data on specific chronic diseases.[@b25-dmso-4-401] Data are collected in clinical practice settings by physicians who provide relevant information on consecutive patients who consulted for the disease of interest. Patients are invited to participate by completing questionnaires on symptoms, expectations, and QOL. The current analysis, which is based on the Neuropathic Pain III DSP conducted in 2008 in Europe among patients with a variety of neuropathic pain conditions, focuses on the subset of patients who were identified with a confirmed diagnosis of pDPN. Data are included from subjects from France, Germany, Italy, and the United Kingdom. Physician practices captured by this DSP were those in primary care as well as the following specialties: neurology, anesthesiology, diabetology, orthopedic surgery, and rheumatology.

Outcomes
--------

In contrast to other studies that used a single question asking patients to rate their disease severity as mild, moderate, or severe, this analysis did not rely on a direct question, but rather determined pDPN severity based on two questions. The first question asked patients to identify and rate (mild, moderate, and severe) their most common types of neuropathic pain sensations (hot/burning, tingling, aching, shooting, stabbing, sharp, pins and needles, numbness, tight, electrical, dull, other). The second question asked patients to identify painful areas of the body and rate the pain of their most commonly painful body part. While patients could identify multiple body locations of pain, only a single body part was considered for pain severity. When considering the overall rating of pDPN severity, the default was severity of neuropathic pain sensations if there was discordance between the two ratings.

Patient-reported pain severity and interference with function was captured using the Brief Pain Inventory-Short Form (BPI-SF).[@b26-dmso-4-401] Four questions focus on pain severity using a 0--10 numerical rating scale (NRS; 0 = no pain, 10 = pain as bad as you can imagine): worst, least, average, and current pain with a 24-hour recall period for the first three items. Patients were stratified as having mild, moderate, or severe pain using the cut points of 0--3, 4--6, and 7--10, respectively, which were previously identified in patients with pDPN.[@b20-dmso-4-401] Seven items on the BPI-SF measure pain interference with daily function (0 = does not interfere, 10 = completely interferes), including sleep. Pain severity and pain interference with daily function were assessed by averaging the four pain severity items and the seven pain interference items, respectively. Additionally, evaluation of pDPN severity on sleep was specifically evaluated using the appropriate item from the BPI-SF for patient-reported sleep, and physician's assessment based on the question "In your opinion to what extent does the patient's neuropathic pain interfere with sleep?"

Work productivity was captured using the Work Productivity and Activity Impairment scale (WPAI).[@b27-dmso-4-401] The WPAI consists of six questions with the first question on employment status. The remaining five questions, referenced to the past 7 days, relate to hours missed because of neuropathic pain; hours missed because of other reasons; hours actually worked; degree neuropathic pain affected productivity while working (rating scale from 0 = no effect to 10 = completely prevented from working); and degree neuropathic pain affected regular activities (rating scale 0 = no effect to 10 = completely prevented daily activities). By summing and dividing these responses accordingly, the percent work time missed due to pDPN (absenteeism) can be calculated, as well as the percent impairment while on the job due to this condition (presenteeism), percent overall work impairment and the percent activity impairment due to their condition. Costs, in euros and dollars, due to lost productivity were calculated using the method of Lofland et al,[@b28-dmso-4-401] based on average annual wages for 2008 in the EU estimated from published sources (<http://data.worldbank.org/indicator/NY.GNP.PCAP.CD>) and the average dollar to euro rate for 2008 (<http://www.irs.gov/businesses/small/international/article/0>,,id=206089,00.html).

Physicians also provided a rating of patient's pDPN severity in response to the question "Which one of these best describes your view of the severity of the patient's neuropathic pain condition?" with potential responses of 1 = mild, 2 = moderate, 3 = severe, 4 = very severe. Physician ratings were obtained independently of the patient's ratings.

Statistical analysis
--------------------

The relationship between severity of neuropathic pain sensations and severity of the most commonly painful body part was specifically evaluated using the nonparametric Spearman rank correlation. Overall patient-reported pDPN severity, stratified by mild, moderate, and severe, was further evaluated for relationships with other patient-reported outcomes. Pre-specified analyses were performed using STATA 10.1 data analysis and statistical software (StataCorp LP, College Station, Texas, USA). Analysis of variance (ANOVA) and *t*-tests were used for interval and count data; chi-squared tests, or Fisher exact test for binary variables were used for categorical data; and Kruskal--Wallis tests or Mann--Whitney tests were conducted on pairwise severity comparisons for ordinal data. All multiple comparisons were Bonferroni corrected. Evidence for statistical significance was based on a *P* value \<0.05.

Results
=======

Patient-reported data were available from 634 individuals identified as having a confirmed diagnosis of pDPN, 162 (25.6%) from France, 230 (36.3%) from Germany, 158 (24.9%) from Italy, and 84 (13.2%) from the UK. Diagnosis was confirmed by a diabetologist or neurologist in 30.1% and 28.3% of cases, respectively, followed by primary care physicians (24.8%); the remaining 16.8% of cases were confirmed by other physician specialties or a combination of physician types. The demographic characteristics of this population, shown in [Table 1](#t1-dmso-4-401){ref-type="table"} indicate that they were predominantly male (56.2%), with a mean age of 63.0 ± 11.4 years, and a mean time since pDPN diagnosis of 1.8 ± 2.1 years; approximately half the population (50.4%) had a body mass index ≥30, indicating obesity. Only 22.4% of subjects reported that they were currently employed; 58.3% were retired, 10.1% were unemployed, and 9.4% stated that they were homemakers.

Pain was reported in multiple body sites in 38.5% of patients. Overall, patients identified the lower extremities (leg or foot) as their most frequent location of neuropathic pain (91.4%). Among patients who reported a single body location for pain (n = 375), 92.8% reported neuropathic pain in the leg or foot.

The proportion of patients who rated their pDPN condition as mild, moderate, and severe was 22.2%, 60.9%, and 16.9%, respectively, and these proportions were similar across the countries ([Figure 1](#f1-dmso-4-401){ref-type="fig"}). The two items used to assess condition severity were strongly correlated (Spearman *r* = 0.7165), with substantial agreement between ratings also indicated by the kappa coefficient (0.6087, 95% CI 0.5504, 0.6670) and the weighted kappa (0.6516, 95% CI 0.5940, 0.7091). There was no association of pDPN severity with demographic variables including age, gender, BMI, or overall employment status. Similarly, there was no association of pDPN severity with disease duration.

For physician-rated severity, since there were only 8 patients who were rated as very severe, these patients were incorporated into the severe category. There was a clear and significant association observed between patient- rated and physician-rated severity (*P* \< 0.0001). However, when analyzed using a 3-by-3 contingency table ([Table 2](#t2-dmso-4-401){ref-type="table"}), ratings showed discrepancies in agreement (kappa = 0.37, 95% CI 0.31, 0.43; weighted kappa = 0.43, 95% CI 0.37, 0.48). Discordance between physician and patient ratings was evident in a substantial proportion of patients across severity categories, and was especially noticeable with physicians underestimating 46.7% of the patients who reported severe pDPN.

Pain severity and pain interference with daily function demonstrated significant increases with increasing pDPN severity ([Figure 2](#f2-dmso-4-401){ref-type="fig"}). Impact on sleep also significantly increased with increasing pDPN severity (*P* \< 0.0001) ([Figure 3](#f3-dmso-4-401){ref-type="fig"}), and all pairwise severity comparisons for both patient and physician assessments of sleep were significant (*P* \< 0.0001).

Among the employed individuals for whom WPAI data were available, there was a significant association between pDPN severity and work productivity (*P* \< 0.05) ([Figure 4](#f4-dmso-4-401){ref-type="fig"}). In particular, the percent overall activity impairment was significantly higher with increasing pDPN severity levels (*P* \< 0.0001 for all pairwise comparisons). Employed individuals reported greater impairment while working and greater overall working impairment at increasing pDPN severity levels, which were significant for mild versus severe (*P* \< 0.001) and moderate versus severe (*P* \< 0.05). Estimated annual costs related to lost work productivity among employed individuals with pDPN increased significantly with pDPN severity ([Figure 5](#f5-dmso-4-401){ref-type="fig"}); €5,646 (\$8,266), €10,552 (\$15,449), and €16,597 (\$24,300) for mild, moderate, and severe pDPN, respectively (overall *P* = 0.0002 and *P* \< 0.05 for all pairwise comparisons). These costs appeared to be primarily driven by presenteeism, ie, impairment while working. Mean total costs of lost productivity across severity categories were €15,446 ± 12,272 (\$10,549 ± 8,383) and were similar among the countries; €8,185 ± 6,376 (\$11,984 ± 9,335) for Italy, €10,789 ± 8,823 (\$15,797 ± 12,918) for France, €10,828 ± 9,042 (\$15,853 ± 13,238) for Germany, and €12,438 ± 8,573 (\$18,211 ± 12,552) for the UK.

Discussion
==========

An understanding of the relationship between pDPN severity and other outcomes affected by this condition can help characterize the disease burden and enhance development and application of appropriate management strategies. The results presented here, which represent a subset of patients with pDPN from a survey of patients with neuropathic pain conditions, provide a European perspective and expand on previous studies that showed a significantly greater patient burden associated with pDPN at higher pain severity levels.[@b9-dmso-4-401],[@b11-dmso-4-401] In contrast to those studies, which specifically evaluated pain severity, the current analysis included more than just pain to define pDPN as a condition, with particular emphasis on neuropathic pain-related symptoms. Importantly, the strong correlation between severity of sensations and body part severity suggests that pain is not the sole component driving the rating of pDPN severity. Additionally, these results show that pDPN severity correlated well with pain, sleep, interference with function, and work productivity.

Information on body regions affected by pDPN is lacking. One study, in a small number of patients, reported that neuropathic pain was always located in the feet,[@b29-dmso-4-401] and evidence from other studies suggested that trigeminal and facial nerves may also be affected.[@b30-dmso-4-401],[@b31-dmso-4-401] While the lower extremities were the most commonly reported source of neuropathic pain in the current study, the anatomic location of neuropathic pain was not limited to this region of the body, and approximately half the patients reported neuropathic pain in other body parts, although quantitative sensory testing or neurophysiology to confirm the presence of neuropathic pain was not performed.

As pDPN severity increased, there was a corresponding increase in pain severity, pain interference with daily function, sleep, employment status, and work-related productivity impairment. Notably, with increasing pDPN severity, the change in pain severity was matched by the change in pain interference with function, suggesting close association between the patient's perception of pDPN with that of both pain and functional ability. Pain interference at each pDPN severity level in the current study was within the range of values reported in previous studies for increasing pain severity levels.[@b9-dmso-4-401],[@b11-dmso-4-401]

Especially notable was the significant association between pDPN severity and pain-related sleep interference, which was consistent with a previous study that showed greater sleep impairment at higher levels of pain severity.[@b9-dmso-4-401] These associations are of clinical relevance given that pDPN not only results in substantial sleep impairment,[@b32-dmso-4-401] but that sleep impairment has been shown to have a direct relationship with metabolic control, including increased risk for and severity of diabetes.[@b33-dmso-4-401]

Among patients who remained in the workforce, severity of pDPN was associated with lost productivity. Interestingly, previous research has shown that among employed individuals with diabetes, those having neuropathic symptoms have significantly greater work loss than those without these symptoms.[@b6-dmso-4-401]

Our data suggest that among employed individuals, the magnitude of work loss increases with pDPN severity, and that most of this lost productivity is derived from impairment while at work, ie, presenteeism. Patients with moderate severity reported that approximately one-third of their work time (36.8%) was lost due to pDPN, and almost twice as much lost work time (58.9%) was lost by patients with severe pDPN. These trends were similar to those observed in a US study that reported on pain severity and productivity in patients with pDPN.[@b21-dmso-4-401] Additionally, these observations are consistent with the suggestion that presenteeism is the primary source of lost productive time, and is also likely to be the primary driver of indirect costs among workers with chronic pain conditions.[@b34-dmso-4-401] In fact, indirect costs associated with lost productivity in the current study were significantly associated with pDPN severity, with indirect costs for a patient with severe pDPN (€16,597) approximately three times that of a patient with mild pDPN (€5,646).

Although there was some agreement between patient- and physician-rated pDPN severity (weighted kappa = 0.43), there was a substantial disparity between the physicians' and patients' ratings, with approximately one-third of patients' ratings being over- or under-rated by physicians, including almost half of the patients who rated themselves as severe being rated by the physicians as mild or moderate. This result is consistent with the general finding in other conditions that clinicians and patients have different perspectives of severity, both underestimating and over-estimating specific outcomes or overall disease severity.[@b23-dmso-4-401],[@b35-dmso-4-401]--[@b41-dmso-4-401] Such an effect, where physicians underestimate the severity of a patient's condition, can conceivably result in a proportion of patients not receiving appropriate treatment. Conversely, if overestimated, the patients may receive medications that are not needed, unnecessarily increasing the risks that may be associated with specific medications.

Although the questions used to determine patient-rated severity were specific for neuropathic pain, it is possible that other factors contributed to these ratings and may in part account for the discordance between patient and physician ratings. In particular, the presence of pain-related comorbidities as well as neuropsychiatric conditions such as depression and anxiety, which were present in this population, could potentially have an influence on patient perceptions of pDPN. Nevertheless, this disparity has several clinical implications, including the need for identifying factors contributing to severity that may be emphasized differentially by patients and physicians. This discrepancy strongly argues for the importance of the patient's perspective, and suggests that physicians need to work closely with patients to gain a comprehensive assessment.

Interpretation and extrapolation of these results are subject to several limitations, including the fact that participation was based on agreement by physicians and patients. It is therefore possible that individuals who participated may have characteristics and perceptions different from those who refused to participate, thereby introducing selection bias and reducing generalizability.

While the population was drawn from a sample of patients with neuropathic pain, the demographics suggest that these patients are likely to be representative of patients with pDPN in the general diabetes population; older age, predominantly male, and with a presence of risk factors for diabetes including obesity, hypertension, and hypercholesterolemia.

Recall bias when completing a questionnaire is another potential limitation, which was minimized for all of the measures by using a maximum recall period of the past 7 days. Furthermore, because the data are only from 4 countries they may not necessarily be representative of the European population, indicating the need for broader sampling.

That the type of employment was not captured in the questionnaire may also be considered a limitation, because it is likely to affect the magnitude of productivity loss among workers as well as the likelihood that employment status was compromised among those who stopped work because of their pDPN. Similarly, the analyses were not adjusted for the specific body parts where patients reported their most commonly occurring pain, because the body site is likely to affect daily function and productivity.

With regard to the diagnosis of pDPN for inclusion, this diagnosis is dependent on the diagnostic skill of the treating physician. Although diabetologists and neurologists were the diagnosing physicians in more than half the patients, the basis for the diagnosis (ie, quantitative sensory testing, neurography, etc) was not captured as part of the study, and therefore it is possible that misdiagnosis may have occurred in a small proportion of the sample population.

It should be noted that the cross-sectional nature of DSPs precludes causation. Since no cause and effect imputation can be made, the observed relationships should be considered associative rather than causal.

Conclusion
==========

Severity of pDPN was significantly associated with pain, sleep, function, and lost productivity; poorer function and sleep, and lower productivity were reported at higher pDPN severity levels, with lower productivity also having a greater economic impact. In a proportion of patients there was substantial discordance between physician and patient ratings of pDPN severity. Further analyses of these observed relationships are warranted from the perspectives of both the patients and clinicians with the goal of refining targeted management strategies to meet the needs of the patients.

**Disclosure**

This study was funded by Pfizer Inc. Messers Taylor-Stokes and Pike are full-time employees of Adelphi, who were paid consultants to Pfizer in connection with the analysis and development of this manuscript. Dr Sadosky and Ms Chandran are employees of Pfizer Inc. Dr Toelle was involved in all aspects of the project, but was not financially compensated for his collaboration. Editorial support was provided by E Jay Bienen, who was funded by Pfizer Inc.

![Proportion of patients rating their painful diabetic peripheral neuropathy as mild, moderate, and severe.](dmso-4-401f1){#f1-dmso-4-401}

![Relationship between self-reported severity of painful diabetic peripheral neuropathy and the Brief Pain Inventory Severity Indices.\
**Notes:** \*^,†^*P* \< 0.0001 for all pairwise comparisons between severity levels.](dmso-4-401f2){#f2-dmso-4-401}

![Relationship between self-reported severity of painful diabetic peripheral neuropathy and impact of pain on sleep.\
**Notes:** *P* \< 0.0001 for overall effect within patient and physician ratings; \*^,†^*P* \< 0.0001 for all pairwise comparisons between severity levels.\
**Abbreviations:** CI, confidence interval; pDPN, painful diabetic peripheral neuropathy.](dmso-4-401f3){#f3-dmso-4-401}

![Relationship between self-reported severity of painful diabetic peripheral neuropathy and productivity assessed using the Work Productivity and Activity Impairment (WPAI) scale.[@b27-dmso-4-401]\
**Notes:** \**P* \< 0.05; ^†^*P* \< 0.001 for overall effect.\
**Abbreviation:** CI, confidence interval.](dmso-4-401f4){#f4-dmso-4-401}

![Relationship between self-reported severity of painful diabetic peripheral neuropathy and indirect costs resulting from lost productivity.\
**Notes:** *\*P* \< 0.05 for all pairwise comparisons between severity levels; *P* = 0.002 for overall effect.\
**Abbreviation:** pDPN, painful diabetic peripheral neuropathy.](dmso-4-401f5){#f5-dmso-4-401}

###### 

Demographic characteristics of the study population (N = 634)

  Characteristic                                  Value
  ----------------------------------------------- -------------
  Gender, n (%)                                   
   Male                                           355 (56.2)
   Female                                         277 (43.8)
  Age, years                                      
   Mean ± standard deviation                      63.0 ± 11.4
   Range                                          23--89
  Country, n (%)                                  
   France                                         162 (25.6)
   Germany                                        230 (36.3)
   Italy                                          158 (24.9)
   United Kingdom                                 84 (13.3)
  Ethnicity, n (%)                                
   White                                          595 (94.2)
   Non-white                                      37 (5.9)
  Employment status, n (%)                        
   Full-time                                      128 (20.5)
   Part-time                                      11 (1.8)
   Homemaker                                      59 (9.4)
   Retired                                        365 (58.3)
   Unemployed                                     63 (10.1)
  Body mass index                                 
   Mean ± standard deviation, kg/m^2^             27.2 ± 4.8
   ≥30, n (%)                                     318 (50.4)
  Time since diagnosis, years                     
   Mean standard deviation                        1.8 ± 2.1
   Range                                          0--17.3
  Common comorbidities (≥5% of patients), n (%)   
   Hypertension                                   369 (58.2)
   Hypercholesterolemia                           246 (38.8)
   Cardiovascular conditions                      110 (17.4)
   Sleep disorders                                107 (16.9)
   Osteoarthritis                                 95 (15.0)
   Clinical depression                            86 (13.6)
   Feelings of depression                         66 (10.4)
   Clinical anxiety                               48 (7.8)
   Feelings of anxiety                            44 (6.9)

**Note:** Numbers may not add up to 634 because of missing data.

###### 

Physician-reported versus patient-reported severity of painful diabetic neuropathy as a condition (weighted kappa coefficient = 0.43; 95% confidence interval 0.37, 0.48)

  Patient-reported severity               Physician-reported severity, n   Row total, n (%)   pDPN severity discordance, percent of patients                
  --------------------------- ----------- -------------------------------- ------------------ ------------------------------------------------ ------------ ------
  Mild                        Frequency   80                               52                 6                                                138 (22.0)   42.0
  Moderate                    Frequency   45                               268                70                                               383 (61.2)   30.0
  Severe                      Frequency   3                                46                 56                                               105 (16.8)   46.7
  Column total, n (%)                     128 (20.5)                       366 (58.5)         132 (21.1)                                       626 (100)    35.5

**Note:** Includes "very severe" (n = 8).

**Abbreviation:** pDPN, painful diabetic peripheral neuropathy.
